Thursday, February 9, 2012
GlobeImmune Inc., of Louisville, Colo., said it started a Phase I trial of GI-6301 , a Targmogen candidate, in patients with metastatic cancers containing brachyury protein, which is overexpressed in tumor types such as breast, colon, lung and prostate cancers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.